{
}
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of promising developments in its research pipeline, favoring AstraZeneca as a buy instead.
UBS has downgraded Novartis from "Buy" to "Neutral," reflecting a shift in its investment outlook. The bank has also reduced its target price for the pharmaceutical company from 111 to 104 Swiss francs.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of significant new developments in the research pipeline for 2025, favoring AstraZeneca as a buy instead.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of promising developments in its research pipeline for 2025, favoring AstraZeneca as a buy instead.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of significant new developments in its research pipeline for 2025, favoring AstraZeneca as a better investment option.
Novartis AG is a leading global pharmaceutical company, with sales primarily in oncology (29.3%), immunology (18.5%), and cardiovascular, renal, and metabolic diseases (17%). The company operates over 30 production sites worldwide, with sales distributed across Europe (30.9%), the USA (42%), and Asia-Africa-Australasia (20%). Additionally, 25.8% of sales come from contract manufacturing.
UBS has downgraded Novartis from Buy to Neutral, lowering the price target from CHF111 to CHF104, citing concerns over upcoming patent expirations that could slow growth. Despite a strong product portfolio and solid financial health, the company faces challenges that may impact its market performance by mid-2025. Additionally, Novartis is nearing EU antitrust approval for its $16.5 billion acquisition of Catalent, which could enhance its manufacturing capabilities.
UBS has downgraded Novartis shares from Buy to Neutral, lowering the target price from CHF 111 to CHF 104, citing concerns over upcoming patent expirations that could slow growth. Despite a strong product portfolio and solid financial health, the company faces challenges that may impact its stock performance beyond mid-2025. Additionally, Novartis is nearing EU antitrust approval for its $16.5 billion acquisition of Catalent, which aims to enhance its manufacturing capabilities.
UBS analyst Matthew Weston has downgraded Novartis (NOVN:SW) (NYSE: NVS) from Buy to Neutral, setting a new price target of CHF 104.00. This change reflects a shift in the firm's outlook on the pharmaceutical giant as of February 13, 2025.
Swiss bank shares experienced mixed downgrades, with Deutsche Bank upgrading UBS to a BUY rating and a price target of CHF 37, while Kepler Cheuvreux downgraded Julius Baer to HOLD with a reduced target of CHF 58. The market showed slight gains for UBS and Novartis, while Landis+Gyr faced a significant drop following a profit warning.
Novartis AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
UBS downgrades Novartis to neutral amid patent expiry concerns
09:05 13.02.2025
ubs downgrades novartis to neutral and lowers target price
08:14 13.02.2025
ubs downgrades novartis to neutral lowers price target to 104 francs
08:05 13.02.2025
ubs downgrades novartis to neutral lowers price target to 104 francs
08:05 13.02.2025
UBS downgrades Novartis to neutral amid patent expiries and weak pipeline
Swiss Franc
Novartis AG
AstraZeneca PLC
CHE
Warren Buffett
Matthew Weston
Hubert Dichtl
Thomas Müller
Show more
07:46 13.02.2025
novartis ag faces challenges as ub s downgrades outlook on pharmaceutical sales
07:37 13.02.2025
ubs downgrades novartis stock rating and lowers price target amid challenges
07:22 13.02.2025
ubs downgrades novartis shares amid patent expirations and market challenges
07:04 13.02.2025
ubs downgrades novartis to neutral with price target of chf104
06:15 13.02.2025
swiss bank shares face downgrades as UBS receives mixed analyst ratings
United States Dollar
Euro
Swiss Franc
Julius Bär Gruppe AG
Novartis AG
CHE
Christina Johansson
Stefan Bollinger
08:05 11.02.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: